Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform shows approved-linked disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt O00329. Start with chronic lymphocytic leukemia, then reuse UniProt O00329 as the stable protein anchor across project notes and exports.
Start with chronic lymphocytic leukemia, then reuse UniProt O00329 as the stable protein anchor across project notes and exports.
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform shows approved-linked disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block. 8 linked drugs remain visible in the same block.
Start review with chronic lymphocytic leukemia because it currently carries approved-linked support. Linked drugs include AMG-319, COPANLISIB, DUVELISIB MONOHYDRATE, IDELALISIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
Review this target as Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform, mapped to UniProt O00329. Sequence length is 1044 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform as ChEMBL target CHEMBL3130, mapped to UniProt O00329. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform is the right protein anchor across sources, using UniProt O00329 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why chronic lymphocytic leukemia is currently framed as approved-linked support. It currently carries 8 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | O00329 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform |
| UniProt Accession | O00329 |
| Component Type | Protein |
| Sequence Length | 1044 aa |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
Review this target as Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform, mapped to UniProt O00329. Sequence length is 1044 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform shows approved-linked disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block.
Start review with chronic lymphocytic leukemia because it currently carries approved-linked support. Linked drugs include AMG-319, COPANLISIB, DUVELISIB MONOHYDRATE, IDELALISIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL1236962 | 10.7 | Ki | 0.02 | Clinical |
| CHEMBL4441003 | 10.4 | IC50 | 0.04 | Preclinical |
| CHEMBL5947580 | 10.37 | IC50 | 0.043 | Preclinical |
| CHEMBL5806327 | 10.37 | IC50 | 0.043 | Preclinical |
| CHEMBL3704739 | 10.32 | IC50 | 0.048 | Preclinical |
| CHEMBL1236962 | 10.22 | IC50 | 0.06 | Clinical |
| CHEMBL2387080 | 10.1 | Ki | 0.079 | Clinical |
| CHEMBL4434674 | 10.1 | Ki | 0.07943 | Preclinical |
| CHEMBL4434674 | 10.1 | IC50 | 0.08 | Preclinical |
| CHEMBL5878158 | 10.07 | IC50 | 0.086 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 625 | 6,320 | 7.4 |
| cell-based format | 173 | 837 | 7.1 |
| assay format | 61 | 371 | 6.4 |
| tissue-based format | 26 | 183 | 7.3 |
| subcellular format | 15 | 1 | 8.2 |
| organism-based format | 1 | 15 | 6.2 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 4 | 2 | 6.8 |
| cell-based format | 3 | 2 | 7.0 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 2 | 1 | 6.7 |
| single protein format | 2 | 5 | 6.5 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 2 | 6.1 |